Ascletis Pharma Reports Positive Results From ASC50 Psoriasis Trial

MT Newswires Live09-29 13:39

Ascletis Pharma (HKG:1672) said its oral small-molecule IL-17A inhibitor ASC50 showed positive results in a 28-day proof-of-concept clinical trial in the U.S. for patients with mild-to-moderate plaque psoriasis, according to a Tuesday filing with the Hong Kong bourse.

The once-daily 200 mg treatment achieved a 48.9% placebo-adjusted reduction in psoriasis area and severity index, or PASI, score after 28 days.

The reduction increased to 60.7% six days after the final dose and 65.9% 15 days after the final dose, the filing said.

The treatment was safe and well tolerated, with all adverse events reported as mild and transient.

Shares of the pharmaceutical firm were down nearly 2% in Tuesday morning trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2671293640?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-29 13:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2671293640","market":"nz","top_or_hot":-1,"title":"Ascletis Pharma Reports Positive Results From ASC50 Psoriasis Trial","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma</a> (HKG:1672) said its oral small-molecule IL-17A inhibitor ASC50 showed positive results in a 28-day proof-of-concept clinical trial in the U.S. for patients with mild-to-moderate plaque psoriasis, according to a Tuesday filing with the Hong Kong bourse.</p><p>The once-daily 200 mg treatment achieved a 48.9% placebo-adjusted reduction in psoriasis area and severity index, or PASI, score after 28 days.</p><p>The reduction increased to 60.7% six days after the final dose and 65.9% 15 days after the final dose, the filing said.</p><p>The treatment was safe and well tolerated, with all adverse events reported as mild and transient.</p><p>Shares of the pharmaceutical firm were down nearly 2% in Tuesday morning trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma Reports Positive Results From ASC50 Psoriasis Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma Reports Positive Results From ASC50 Psoriasis Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-29 13:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma</a> (HKG:1672) said its oral small-molecule IL-17A inhibitor ASC50 showed positive results in a 28-day proof-of-concept clinical trial in the U.S. for patients with mild-to-moderate plaque psoriasis, according to a Tuesday filing with the Hong Kong bourse.</p><p>The once-daily 200 mg treatment achieved a 48.9% placebo-adjusted reduction in psoriasis area and severity index, or PASI, score after 28 days.</p><p>The reduction increased to 60.7% six days after the final dose and 65.9% 15 days after the final dose, the filing said.</p><p>The treatment was safe and well tolerated, with all adverse events reported as mild and transient.</p><p>Shares of the pharmaceutical firm were down nearly 2% in Tuesday morning trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2671293640","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2671293640","pubTimestamp":1790660392,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ascletis Pharma  said its oral small-molecule IL-17A inhibitor ASC50 showed positive results in a 28-day proof-of-concept clinical trial in the U.S. for patients with mild-to-moderate plaque psoriasis, according to a Tuesday filing with the Hong Kong bourse.The once-daily 200 mg treatment achieved a 48.9% placebo-adjusted reduction in psoriasis area and severity index, or PASI, score after 28 days.The reduction increased to 60.7% six days after the final dose and 65.9% 15 days after the final dose, the filing said.The treatment was safe and well tolerated, with all adverse events reported as mild and transient.Shares of the pharmaceutical firm were down nearly 2% in Tuesday morning trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1515":"抗疫概念","BK1161":"生物科技","01672":"歌礼制药-B"},"translate_title":"歌礼制药报告ASC50银屑病试验积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1.5},"content_text":"Ascletis Pharma (HKG:1672) said its oral small-molecule IL-17A inhibitor ASC50 showed positive results in a 28-day proof-of-concept clinical trial in the U.S. for patients with mild-to-moderate plaque psoriasis, according to a Tuesday filing with the Hong Kong bourse.The once-daily 200 mg treatment achieved a 48.9% placebo-adjusted reduction in psoriasis area and severity index, or PASI, score after 28 days.The reduction increased to 60.7% six days after the final dose and 65.9% 15 days after the final dose, the filing said.The treatment was safe and well tolerated, with all adverse events reported as mild and transient.Shares of the pharmaceutical firm were down nearly 2% in Tuesday morning trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2671293640","isCrawlerRequest":true}